Cytokinetics, Inc (
Q3 2010 Earnings Call
October 28, 2010 04:30 pm ET
Sharon Barbari - EVP, Finance & CFO
Robert Blum - President & CEO
Andrew Wolff - SVP, Clinical Research and Development, & CMO
Joel Sendek - Lazard Capital Market
Charles Duncan - JMP Securities
Ritu Baral - Canaccord
Mark Monane - Needham
Greg Wade - Wedbush
Larry Smith - DLS Research
Good afternoon and welcome ladies and gentlemen to the Cytokinetics Third Quarter 2010 Conference Call. At this time I would like to inform you that this call is being recorded and that all participants are in a listen only mode. At the request of the company we'll open the call for question and answers after the presentation.
I will now turn the conference over to Sharon Barbari, Cytokinetics Senior Vice President of Finance and CFO. Please go ahead.
Good afternoon and thank you for joining the Cytokinetics senior management team on this conference call today. Also present during this call are Robert Blum, our President and Chief Executive Officer and after Dr. Andrew Wolff, Senior Vice President of Clinical Research and Development and Chief Medical Officer.
Following the forward-looking statement disclaimer, Robert will provide an overview of the past quarter along with an update on the advancement of our development pipeline focused on the biology of muscle function. Andy will then provide highlights and details on the progress of the company's clinical development program. And then I will provide some brief comments with respect to our financials and our investments and research and development activity.